Psychotropic Medication Use for Youth in Residential Treatment: A Comparison Between Youth with Monopharmacy Versus Polypharmacy

Journal of Child and Family Studies

Volumn 19, Issue 6, 2010, Pages 795-802

  Griffith, Annette K ^a   Huscroft D'Angelo, Jacqueline ^a   Epstein, Michael H ^a   Singh, Nirbhay N ^b   Huefner, Jonathan C ^c   Pick, Robert ^c  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b ONE RESEARCH INSTITUTE   (United States)

^c Boys Town   (United States)

Author keywords

Monopharmacy; Polypharmacy; Psychotropic medication; Residential treatment

Indexed keywords

EID: 78650214112     PISSN: 10621024     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10826-010-9372-9     Document Type: Article

References (35)

1. Achenbach, T. M., & Rescorla, L. A. (2001). Manual for the ASEBA school-age forms and profiles Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families.
2. Breland-Noble, A. M., Elbogen, E. B., Farmer, E. M. Z., Dubs, M. S., Wagner, H. R., & Burns, B. J. (2004). Use of psychotropic medications by youths in therapeutic foster care and group homes. Psychiatric Services, 55, 706-708. doi: 10. 1176/appi. ps. 55. 6. 706.
3. Breland-Noble, A. M., Farmer, E. M. Z., Dubs, M. S., Potter, E., & Burns, B. J. (2005). Mental health and other service use by youth in therapeutic foster care and group homes. Journal of Child and Family Studies, 14, 167-180. doi: 10. 1176/appi. ps. 55. 6. 706.
4. Brown, R. T. (2005). Recent advances in pharmacotherapies for the externalizing disorders. School Psychology Quarterly, 20, 118-134. doi: 10. 1521/scpq. 20. 2. 118. 66515.
5. Child Welfare League of America. (2005). State child welfare agency survey. Washington, DC: Author.
6. Connor, D. F., Barkley, R. A., & Davis, H. T. (2000). A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clinical Pediatrics, 39, 15-25. doi: 10. 1177/000992280003900102.
7. Connor, D. F., & McLaughlin, T. J. (2005). A naturalistic study of medication reduction in a residential treatment setting. Journal of Child and Adolescent Psychopharmacology, 15, 302-310. doi: 10. 1089/cap. 2005. 15. 302.
8. Connor, D. F., & Meltzer, B. M. (2006). Pediatric psychopharmacology: Fast facts. New York: WW Norton & Co.
9. Connor, D. F., Ozbayrak, K. R., Kusiak, K. A., & Caponi, A. B. (1997). Combined pharmacotherapy in children and adolescents in a residential treatment center. Journal of the American Academy of Child & Adolescent Psychiatry, 36, 248-254. doi: 10. 1097/00004583-199702000-00016.
10. Cull, J. G., & Gill, W. S. (1988). Suicide probability scale (SPS) manual. Los Angeles: Western Psychological Services.
11. Dean, A. J., McDermott, B. M., & Marshall, R. T. (2006). Psychotropic medication utilization in a child and adolescent mental health service. Journal of Child and Adolescent Psychopharmacology, 16, 273-285. doi: 10. 1089/cap. 2006. 16. 273.
12. DelBello, M. P., Kowatch, R. A., Adler, C. M., Stanford, K. E., Welge, J. A., Barzman, D. H., et al. (2006). A double-blind randomized pilot study comparing Quetiapine and Divalproex for adolescent mania. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 305-313. doi: 10. 1097/01. chi. 0000194567. 63289. 97.
13. Duppong Hurley, K., Trout, A., Chmelka, M. B., Burns, B. J., Epstein, M. H., Thompson, R. W., et al. (2009). The changing mental health needs of youth admitted to residential group care: Comparing mental health status at admission for youth in 1995 and 2004. Journal of Emotional & Behavioral Disorders, 17, 164-176. doi: 10. 1177/1063426608330791.
14. Emslie, G. J., Kennard, B. D., Mayes, T. L., Nightingale-Teresi, J., Carmody, T., Hughes, C. W., et al. (2008). Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. The American Journal of Psychiatry, 165, 459-467. doi: 10. 1176/appi. ajp. 2007. 07091453.
15. Epstein, M. H. (2004). Behavioral and Emotional Rating Scale: A strength-based approach to assessment (2nd ed.). Austin, TX: PRO-ED.
16. Faraone, S. V., Short, E. J., Biederman, J., Findling, R. L., Roe, C., & Manos, M. J. (2002). Efficacy of adderall and methylphenidate in attention deficit hyperactivity disorder: A drug-placebo and drug-drug response curve analysis of a naturalistic study. International Journal of Neuropsychopharmacology, 5(2), 121-129. doi: 10. 1017/S1461145702002845.
17. Greenhill, L. L. (2002). Stimulant medication treatment of children with attention deficit hyperactivity disorder. In J. R. Cooper (Ed.), Attention deficit hyperactivity disorder: State of the science-best practices (pp. 9-1-9-27). Kingston, NJ: Civic Research Institute.
18. Handwerk, M. L., Smith, G. L., Thompson, R. W., Spellman, D. F., & Daly, D. L. (2008). Psychotropic medication utilization at a group-home residential facility for children and adolescents. Journal of Child and Adolescent Psychopharmacology, 18, 517-525. doi: 10. 1089/cap. 2008. 012.
19. Hawkins, R. P., Almeida, M. C., Fabry, B., & Reitz, A. L. (1992). A scale to measure restrictiveness of living environments for troubled children and youths. Hospital & Community Psychiatry, 43, 54-58.
20. Leo, J. (2006). The truth about academic medicine: Children on psychotropic drugs and the illusion of science. In S. Timimi & B. Maitra (Eds.), Critical voices in child and adolescent mental health (pp. 107-127). Free Association Books: London.
21. March, J. S., & Vitiello, B. (2009). Clinical messages from the treatment for adolescents with depression study (TADS). The American Journal of Psychiatry, 166, 1118-1123. doi: 10. 1176/appi. ajp. 2009. 08101606.
22. Martin, A., van Hoof, T., Stubbe, D., Sherwin, T., & Scahill, M. C. (2003). Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. Psychiatric Services, 54, 72-77. doi: 10. 1176/appi. ps. 54. 1. 72.
23. Najjar, F., Welch, C., Grapentine, W. L., Sachs, H., Siniscalchi, J., & Price, L. H. (2004). Trends in psychotropic drug use in a child psychiatric hospital from 1991-1998. Journal of Child and Adolescent Psychopharmacology, 14, 87-93. doi: 10. 1089/104454604773840526.
24. Pataki, C. S., Carlson, G. A., Kelly, K. L., Rapport, M. D., & Biancaniello, L. (1993). Side effects of methylphenidate and desipramine alone and in combination in children. Journal of the American Academy of Child & Adolescent Psychiatry, 32, 1065-1072. doi: 10. 1097/00004583-199309000-00028.
25. Pavkov, T. W., & Walrath, C. M. (2008). Clinical and non-clinical characteristics associated with medication use among children with serious emotional disturbance. Journal of Child and Family Studies, 17, 839-852. doi: 10. 1007/s10826-008-9193-2.
26. Pottick, K. J., Warner, L. A., & Yoder, K. A. (2005). Youths living away from families in the US mental health system: Opportunities for targeted intervention. Journal of Behavioral Health Services & Research, 32, 264-281. doi: 10. 1007/BF02291827.
27. Preskhorn, S. H. (1995). Should rational drug development in psychiatry target more than one mechanism of action in a single molecule? International Review of Psychiatry, 7, 17-28. doi: 10. 3109/09540269509022972.
28. Preskhorn, S. H., & Lacey, R. L. (2007). Polypharmacy: When is it rational? Journal of Psychiatric Practice, 13, 97-105. doi: 10. 1097/01. pra0000265766. 25495. 3b.
29. Ryan, J. B., Reid, R., & Ellis, C. (2008). Special educators' knowledge regarding psychotropic interventions for students with emotional and behavioral disorders. Remedial and Special Education, 29, 269-279. doi: 10. 1177/0741932507313015.
30. Safer, D. J., Zito, J. M., & dosReis, S. (2003). Concomitant psychotropic medication for youths. American Journal of Psychiatry, 160, 438-449. doi: 10. 1176/appi. ajp. 160. 3. 438.
31. Stigler, K. A., & McDougle, C. J. (2008). Pharmacotherapy of irritability in pervasive developmental disorders. Child and Adolescent Psychiatric Clinics of North America, 17, 739-752. doi: 10. 1016/j. chc. 2008. 06. 002.
32. Turgay, A., Binder, C., Snyder, R., & Fisman, S. (2002). Long-term safety and efficacy of Risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics, 110, e34. doi: 10. 1542/peds. 110. 3. e34.
33. van Bellinghen, M., & De Troch, C. (2001). Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology, 11, 5-13. doi: 10. 1089/104454601750143348.
34. Vitiello, B. (2007). Research in child and adolescent psychopharmacology: Recent accomplishments and new challenges. Psychopharmacology, 191, 5-13. doi: 10. 1007/s00213-006-0414-3.
35. Zito, J. M., Safer, D. J., Sai, D., Gardner, J. F., Thomas, D., Coombes, P., et al. (2008). Psychotropic medication patterns among youth in foster care. Pediatrics, 121, 157-163. doi: 10. 1542/peds. 2007-0212.